- Home
- ETON vs BOLD Comparison
ETON vs BOLD Comparison
Compare ETON & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETON
- BOLD
- Stock Information
- Founded
- ETON 2017
- BOLD 2018
- Country
- ETON United States
- BOLD United States
- Employees
- ETON N/A
- BOLD N/A
- Industry
- ETON Biotechnology: Pharmaceutical Preparations
- BOLD
- Sector
- ETON Health Care
- BOLD
- Exchange
- ETON Nasdaq
- BOLD Nasdaq
- Market Cap
- ETON 199.5M
- BOLD 81.0M
- IPO Year
- ETON 2018
- BOLD 2024
- Fundamental
- Price
- ETON $8.82
- BOLD $2.95
- Analyst Decision
- ETON Strong Buy
- BOLD Strong Buy
- Analyst Count
- ETON 3
- BOLD 3
- Target Price
- ETON $12.00
- BOLD $23.00
- AVG Volume (30 Days)
- ETON 214.1K
- BOLD 57.8K
- Earning Date
- ETON 11-11-2024
- BOLD 11-11-2024
- Dividend Yield
- ETON N/A
- BOLD N/A
- EPS Growth
- ETON N/A
- BOLD N/A
- EPS
- ETON N/A
- BOLD N/A
- Revenue
- ETON $31,381,000.00
- BOLD N/A
- Revenue This Year
- ETON $19.61
- BOLD N/A
- Revenue Next Year
- ETON $35.39
- BOLD N/A
- P/E Ratio
- ETON N/A
- BOLD N/A
- Revenue Growth
- ETON 8.14
- BOLD N/A
- 52 Week Low
- ETON $3.03
- BOLD $2.82
- 52 Week High
- ETON $8.66
- BOLD $15.24
- Technical
- Relative Strength Index (RSI)
- ETON 76.07
- BOLD N/A
- Support Level
- ETON $7.58
- BOLD N/A
- Resistance Level
- ETON $8.66
- BOLD N/A
- Average True Range (ATR)
- ETON 0.42
- BOLD 0.00
- MACD
- ETON -0.07
- BOLD 0.00
- Stochastic Oscillator
- ETON 91.49
- BOLD 0.00
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.